By: Benzinga
UPDATE: Piper Jaffray Says Affymax May Run Out of Cash as Early as the Second-Quarter
In a note released late Tuesday morning, Piper Jaffray Analyst Ian Somaiya stated that Affymax (NASDAQ: AFFY ) has no timeline for the re-introduction of its recently pulled drug Omontys, and had no estimate on when the investigation into the drug would end. With Omontys off the market, Amgen's (NASDAQ:
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here